Plant Infrastructure


Product delivery and quality assurance are business critical functions that Maxheal performs in compliance with industry and regulatory requirements. Maxheal quality systems provide validation, change control, production support, documentation control and other cGMP services to both the plant and to our customers. Our success as a Pharma leader has been fuelled by our pioneering approach to bolster our early- and mid-stage research and pipeline through a series of acquisitions, collaborations, alliances and agreements. They have helped balance our portfolio and build clusters of expertise in key therapeutic areas where there is great unmet medical need. We acquired skilled people, great science, potential products and in some areas, marketed products. And we've positioned ourselves as a strong partner in our circles by demonstrating our ability to nurture innovation, assets and talent.

Nashik

Nashik, an industrial hub of Maharashtra, is at about 180Km (112 Miles) from Mumbai and well connected by road and rail transport. It is the location of Maxheal Group's flagship company Maxheal Pharmaceuticals (India) Ltd. Started as a small scale unit with bare minimum manufacturing facilities, is today one of the fastest growing pharmaceutical company in the region.

 

Unit Details
TOTAL SITE AREA 2788 Sq Mt.
TOTAL CONSTRUCTED AREA 2300 Sq Mt.
QC & QA AREA 175 Sq Mt.
FACILITIES ◊ Tablets ◊ Capsules ◊ Dry Syrup ◊ β- Lactum ◊ Cephalosporins
EMPLOYEE STRENGTH 200 to 250
FACILITIES PLANNED Veterinary Tablets
ANNUAL MANUFACTURING CAPACITY ◊ Tablets - 750 million
◊ Capsules (β - Lactum & General) - 900 million
◊ Dry syrup - 5.4 million
ACCREDITATION'S ◊ WHO-cGMP ◊ NAFDAC ◊ FDB-Ghana

Boisar

In response to the changing market scenario and to cope with the steadily increasing demand for high quality pharmaceutical formulations, Maxheal acquired a pre-existing manufacturing unit at Boisar an industrial Zone of Maharashtra, situated 100 kms. from Mumbai.

Ally Pharma Options Pvt. Ltd., a WHO-cGMP unit with approvals from NAFDAC, FDB (Ghana), Kenya, Uganda with infrastructure of par excellence and compatible to international standards. Laid out over 45000 sq. ft. of land, the unit having equally free space for future expansion is added advantage.

 

Unit Details
TOTAL SITE AREA 8361 Sq Mt.
TOTAL CONSTRUCTED AREA 4089 Sq Mt.
QC & QA AREA 250 Sq Mt.
AREA FOR EXPANSION 4022 Sq Mt.
FACILITIES ◊ Tablets ◊ Capsules ◊ Liquid-Oral ◊ Ointment ◊ Dry Syrup ◊ Pellets formation
EMPLOYEE STRENGTH 125 to 150
FACILITIES PLANNED ◊ β- Lactum Unit ◊ Sterile Ointment
ANNUAL MANUFACTURING CAPACITY ◊ Tablets 60 million ◊ Capsules 67.2 million ◊ Bottles 19 million ◊ Tubes 10 million
ACCREDITATION'S ◊ WHO-cGMP ◊ NAFDAC ◊ FDB-Ghana
◊ Food and Poison Board-Kenya ◊ NDA-Uganda

Surat

With a view to keep pace with ever expanding horizons, in 2009 Maxheal introduced an operational third unit viz Maxheal Laboratories Pvt. Ltd., at Special Economic Zone (SEZ), Sachin near Surat. This site having WHO-GMP, NAFDAC, FDB (Ghana) approved unit with infrastructure par excellence compatible with UK-MHRA and team of equally qualified personnel is an added feather in the cap of Maxheal. The plant is well connected by rail, road and air transports and is about 271 KM from Mumbai.

 

Unit Details
TOTAL SITE AREA 14,400 Sq Mt.
TOTAL CONSTRUCTED AREA 14,400 Sq Mt. - 2 Storey building
QC & QA AREA 850 Sq Mt
AREA AVAILABLE FOR EXPANSION 5100 Sq Mt.
FACILITIES ◊ Tablets ◊ Capsules
EMPLOYEE STRENGTH 225 to 250
FACILITIES PLANNED ◊ Injectables ◊ Oral Rehydration Salt ◊ Dry Powder
ANNUAL MANUFACTURING CAPACITY ◊ Tablets 1000 million ◊ Capsules 750 million
PROJECTED MANUFACTURING CAPACITY ◊ Tablets 1000 million ◊ Capsules 750 million
ACCREDITATION'S ◊ WHO-cGMP ◊ NAFDAC ◊ FDB-Ghana

Go to top